Company Filing History:

10 out of 677

Eisai Company, Limited

Eisai R&d Management Co., Ltd.

patents

Years Active: 1983-2021

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11052150 - Method and pharmaceutical composition for treating Crohn's disease (2021-07-06),

2. 7781452 - Imidazopyridine compound (2010-08-24),

3. 5998445 - Pyridine derivatives having anti-ulcerative activity (1999-12-07),

4. 5840910 - Pyridine derivatives having anti-ulcerative activity (1998-11-24),

5. 5708013 - Pyridine derivative and therapeutic agent for ulcer comprising the same (1998-01-13),

6. 5635519 - Benzothiazole compounds which are substituted by pyridymethyl (1997-06-03),

7. 5420144 - Pyridyl substituted benzothiazole compounds which have useful (1995-05-30),

8. 5300518 - Pyridyl substituted benzothiazole compounds which have useful (1994-04-05),

9. 5239079 - Pyridinium salt and pharmacological composition containing the same (1993-08-24),

10. 5162317 - Pyridinium salt and pharmacological composition containing the same (1992-11-10),

11. 5045552 - Pyridine derivatives having anti-ulcerative activity (1991-09-03),

12. 4888439 - Polyprenyl compound and pharmaceutical use (1989-12-19),

13. 4782151 - Polyprenyl compound and pharmaceutical use (1988-11-01),

14. 4382151 - 6,10,14,18-Tetramethly-5,9,13,17-nonadecatetraene-2-ol (1983-05-03),

Title: Kiyoshi Oketani: Innovator in Pharmaceutical Composition

Introduction

Kiyoshi Oketani is a prominent inventor based in Ibaraki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of Crohn's disease. With a total of 14 patents to his name, Oketani's work reflects his dedication to advancing medical science.

Latest Patents

Among his latest patents is a method and pharmaceutical composition for treating Crohn's disease. This invention aims to provide a pharmaceutical composition that includes an anti-fractalkine antibody, which offers therapeutically effective improvement for patients suffering from Crohn's disease. The composition is designed for intravenous administration at a dose of at least 10 mg/kg of human body weight. Another notable patent involves an imidazopyridine compound, represented by a specific general formula, which includes various alkyl and phenyl groups.

Career Highlights

Oketani has worked with notable companies in the pharmaceutical industry, including Eisai Company, Limited and Esai Co., Ltd. His experience in these organizations has allowed him to develop innovative solutions that address critical health issues.

Collaborations

Throughout his career, Oketani has collaborated with esteemed colleagues such as Manabu Murakami and Hideaki Fujisaki. These partnerships have contributed to the success of his inventions and the advancement of pharmaceutical research.

Conclusion

Kiyoshi Oketani's contributions to the field of pharmaceuticals, particularly in the treatment of Crohn's disease, highlight his innovative spirit and commitment to improving patient care. His work continues to inspire advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

1 patent (EPO):

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.